

DOSIMETRY OF BETA RAYS AND LOW-ENERGY PHOTONS FOR BRACHYTHERAPY WITH SEALED SOURCES

CONTENTS

THE INTERNATIONAL COMMISSION ON RADIATION UNITS AND MEASUREMENTS	3
CONTENTS	5
PREFACE	9
SYMBOLS AND ACRONYMS	11
ABSTRACT	13
EXECUTIVE SUMMARY	15
1 INTRODUCTION	17
1.1 Background	17
1.1.1 <i>Historical development of the applications</i>	17
1.1.2 <i>Need for accurate dosimetry</i>	18
1.1.3 <i>Problems of dosimetry</i>	18
1.1.4 <i>Need for the Report</i>	19
1.2 Scope of the Report	19
2 SOURCES AND THEIR APPLICATION IN BRACHYTHERAPY	21
2.1 General	21
2.2 Beta-ray sources	21
2.2.1 <i>Strontium-90/yttrium-90</i>	21
2.2.2 <i>Ruthenium-106/rhodium-106</i>	22
2.2.3 <i>Yttrium-90</i>	22
2.2.4 <i>Phosphorus-32</i>	23
2.2.5 <i>Other beta-emitting nuclides and geometries</i>	24
2.3 Low-energy photon sources	24
2.3.1 <i>Iodine-125</i>	24
2.3.2 <i>Palladium-103</i>	27
2.3.3 <i>Ytterbium-169</i>	27
2.3.4 <i>Samarium-145</i>	27
3 SOURCE SPECIFICATION AND CALIBRATION	29
3.1 Specification of beta-ray sources	29
3.1.1 <i>General</i>	29
3.1.2 <i>Reference absorbed-dose rate</i>	29

DOSIMETRY OF BETA RAYS AND LOW-ENERGY PHOTONS FOR THERAPEUTIC APPLICATIONS

3.1.3	<i>Contained activity</i>	30
3.1.4	<i>Source uniformity</i>	30
3.1.4.1	<i>Planar and concave sources</i>	30
3.1.4.2	<i>Seed and wire sources</i>	31
3.2	Calibration of beta-ray sources	31
3.2.1	<i>General</i>	31
3.2.2	<i>Extrapolation chamber</i>	32
3.2.2.1	<i>General</i>	32
3.2.2.2	<i>Recombination</i>	34
3.2.2.3	<i>Divergence</i>	34
3.2.2.4	<i>Temperature and pressure</i>	34
3.2.2.5	<i>Backscatter correction</i>	34
3.2.2.6	<i>Uncertainties</i>	35
3.2.3	<i>Other methods for determining the reference absorbed-dose rate</i>	35
3.2.3.1	<i>General</i>	35
3.2.3.2	<i>Measurement procedure</i>	36
3.2.3.3	<i>Calibration</i>	36
3.2.3.4	<i>Measurement uncertainties</i>	36
3.3	Specification of low-energy photon sources	36
3.3.1	<i>Reference air-kerma rate</i>	36
3.3.2	<i>Activity</i>	37
3.3.3	<i>Source uniformity</i>	38
3.4	Calibration of low-energy photon sources	38
3.4.1	<i>General</i>	38
3.4.2	<i>Previous approaches</i>	38
3.4.3	<i>Wide-angle free-air chamber</i>	39
3.4.3.1	<i>General</i>	39
3.4.3.2	<i>Recombination</i>	40
3.4.3.3	<i>Attenuation in filter</i>	40
3.4.3.4	<i>Source-to-aperture air attenuation</i>	40
3.4.3.5	<i>Aperture-to-WAFAC air attenuation</i>	40
3.4.3.6	<i>Inverse-square correction for aperture</i>	41
3.4.3.7	<i>Humidity correction</i>	41
3.4.3.8	<i>In-chamber photon scatter</i>	41
3.4.3.9	<i>Source-holder stem-scatter correction</i>	41
3.4.3.10	<i>In-chamber electron-loss correction</i>	41
3.4.3.11	<i>Aperture-penetration correction</i>	41
3.4.3.12	<i>External photon-scatter (build-up) correction</i>	41
3.4.3.13	<i>Uncertainties</i>	41
3.4.4	<i>Implications of changes in reference air-kerma rate calibrations</i>	42
3.5	Traceability of calibrations	42
4	DETERMINATION OF DOSE DISTRIBUTIONS	45
4.1	General Formalism for dose distributions	45
4.1.1	<i>Introduction</i>	45
4.1.2	<i>Formalism for seed and wire sources</i>	45
4.1.3	<i>Application of the formalism for seed and wire sources</i>	47
4.1.4	<i>Formalism for planar and concave sources</i>	48
4.2	Calculation of dose distributions for beta rays	48
4.2.1	<i>Introduction</i>	48
4.2.2	<i>Monte Carlo methods for electron transport</i>	49
4.2.2.1	<i>ETRAN, ITS and MCNP codes</i>	50
4.2.2.2	<i>EGS codes</i>	51
4.2.2.3	<i>Other Monte Carlo codes</i>	51
4.2.2.4	<i>Accuracy</i>	52

CONTENTS

4.2.3	<i>Beta-ray point-source dose functions</i>	52
4.2.3.1	<i>General</i>	52
4.2.3.2	<i>Integration of the beta-ray point-source dose function for clinical source geometries</i>	53
4.2.3.3	<i>Limitations of the integration of the beta-ray point-source dose function for the eye applicators</i>	54
4.3	Calculation of dose distributions for low-energy photons	56
4.4	Measurement of dose distributions	58
4.4.1	<i>General considerations</i>	58
4.4.2	<i>Detectors for relative measurements</i>	58
4.4.2.1	<i>Radiochromic film</i>	58
4.4.2.2	<i>Thermoluminescent dosimeters</i>	59
4.4.2.3	<i>Plastic scintillators</i>	60
4.4.2.4	<i>Diodes</i>	61
4.4.2.5	<i>Alanine dosimeters</i>	61
4.4.2.6	<i>Diamond</i>	61
4.4.2.7	<i>Small-volume ionization chamber</i>	62
4.4.2.8	<i>Polymer gels</i>	62
4.4.3	<i>Phantoms</i>	63
4.5	Applications of dose distributions measured in other media	64
4.5.1	<i>General</i>	64
4.5.2	<i>Beta Rays</i>	64
4.5.3	<i>Photons</i>	66
5	DOSIMETRY COMPARISONS	67
5.1	Comparison of beta-ray source calibrations	67
5.2	Comparison of absorbed-dose distributions	69
5.2.1	<i>Beta-ray sources</i>	69
5.2.1.1	<i>General</i>	69
5.2.1.2	<i>Central-axis depth–dose curves</i>	69
5.2.1.3	<i>Off-axis dose versus depth and position</i>	73
5.2.2	<i>Low-energy photon sources</i>	75
6	COMPILATION OF DOSIMETRIC REFERENCE DATA	77
6.1	General	77
6.2	Dose distributions for beta-ray sources	80
6.3	Dose distributions for low-energy photon sources	84
7	QUALITY CONTROL	85
APPENDIX A:	COMPILED PHYSICAL DATA	87
A.1	Beta rays	87
A.2	Low-energy photon sources	116
A.3	Difference of mass stopping powers and mass energy-absorption coefficients of a given material from that of water	129
APPENDIX B:	THERAPEUTIC APPLICATIONS OF BETA RAYS AND LOW-ENERGY PHOTONS	139
B.1	Treatment of uveal melanoma in ophthalmology	139
B.1.1	<i>Pathology and therapeutic approaches</i>	139
B.1.2	<i>Clinical results (short survey)</i>	139
B.1.2.1	<i>External-beam proton and helium-ion radiotherapy</i>	139
B.1.2.2	<i>^{106}Ru eye-plaque brachytherapy</i>	140
B.1.2.3	<i>^{125}I eye-plaque brachytherapy</i>	140

DOSIMETRY OF BETA RAYS AND LOW-ENERGY PHOTONS FOR THERAPEUTIC APPLICATIONS

<i>B.1.3 Anatomy of the eye</i>	140
<i>B.1.4 The volumes</i>	141
<i>B.1.4.1 Gross tumor volume (GTV)</i>	141
<i>B.1.4.2 Clinical target volume (CTV)</i>	142
<i>B.1.4.3 Planning target volume (PTV)</i>	142
<i>B.1.5 Technique of brachytherapy plaques</i>	142
<i>B.1.6 Reporting brachytherapy applications for uveal melanoma</i>	143
<i>B.1.6.1 Specification of the ^{106}Ru plaques</i>	143
<i>B.1.6.2 Specification of the ^{125}I seeds</i>	143
<i>B.1.6.3 Reporting irradiation of the CTV (or patient)</i>	144
B.2 Intravascular brachytherapy	144
<i>B.2.1 Rationale</i>	144
<i>B.2.2 Therapeutic approaches and present trends</i>	145
<i>B.2.2.1 Brachytherapy techniques</i>	145
<i>B.2.2.2 Treatment of de novo lesions</i>	146
<i>B.2.2.3 Treatment of in-stent restenosis</i>	148
<i>B.2.2.4 Remaining issues</i>	149
<i>B.2.2.5 Tentative conclusions</i>	149
<i>B.2.3 Reporting intravascular brachytherapy</i>	150
<i>B.2.3.1 General recommendations for reporting radiation therapy</i>	150
<i>B.2.3.2 Specification of the sources</i>	150
<i>B.2.3.3 Patient data: lengths and volumes</i>	151
<i>B.2.3.4 Summary of recommendations for reporting intravascular brachytherapy</i>	154
APPENDIX C: CALCULATION OF BETA-RAY DOSE DISTRIBUTIONS BY INTEGRATION OF THE BETA-RAY POINT-SOURCE DOSE FUNCTION	155
C.1 Beta-ray point-source functions	155
<i>C.1.1 General</i>	155
<i>C.1.2 The original Loevinger point-source dose function</i>	155
<i>C.1.3 The Vynckier–Wambersie function</i>	156
<i>C.1.4 The Loevinger function with a constant end-of-range term (Cross function)</i>	156
C.2 Integration of the beta-ray point-source dose function	157
<i>C.2.1 General</i>	157
<i>C.2.2 Infinite thin plane-disk sources</i>	158
<i>C.2.3 Cylindrical sources (line sources)</i>	158
<i>C.2.4 Spherical sources</i>	160
<i>C.2.5 Numerical integration of the beta point-source dose function for eye plaques</i>	163
REFERENCES	165